Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R, Moser RD, Park H, Gurley KE, Kao MC, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2018 Jun 15;24(12):2828-2843. doi: 10.1158/1078-0432.CCR-17-1339. Epub 2018 Mar 29.

2.

Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation.

Gurley KE, Ashley AK, Moser RD, Kemp CJ.

Cell Death Differ. 2017 Nov;24(11):1853-1860. doi: 10.1038/cdd.2017.107. Epub 2017 Jul 7.

3.

Induction of Liver Tumors in Mice with N-Ethyl-N-Nitrosourea or N-Nitrosodiethylamine.

Gurley KE, Moser RD, Kemp CJ.

Cold Spring Harb Protoc. 2015 Oct 1;2015(10):941-2. doi: 10.1101/pdb.prot077438.

PMID:
26430250
4.

Induction of Colon Cancer in Mice with 1,2-Dimethylhydrazine.

Gurley KE, Moser RD, Kemp CJ.

Cold Spring Harb Protoc. 2015 Sep 1;2015(9):pdb.prot077453. doi: 10.1101/pdb.prot077453.

PMID:
26330619
5.

Induction of Lung Tumors in Mice with Urethane.

Gurley KE, Moser RD, Kemp CJ.

Cold Spring Harb Protoc. 2015 Sep 1;2015(9):pdb.prot077446. doi: 10.1101/pdb.prot077446.

PMID:
26330618
6.

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.

Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, Fredlund E, Quigley DA, Adams DJ, Balmain A.

Nature. 2015 Jan 22;517(7535):489-92. doi: 10.1038/nature13898. Epub 2014 Nov 2.

7.

Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.

8.

CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer.

Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, Filippova GN.

Cell Rep. 2014 May 22;7(4):1020-9. doi: 10.1016/j.celrep.2014.04.004. Epub 2014 May 1.

9.

ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.

Busch SE, Moser RD, Gurley KE, Kelly-Spratt KS, Liggitt HD, Kemp CJ.

Oncogene. 2014 May 15;33(20):2665-73. doi: 10.1038/onc.2013.208. Epub 2013 Jun 10.

10.

ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Busch SE, Gurley KE, Moser RD, Kemp CJ.

J Pathol. 2012 Jul;227(3):298-305. doi: 10.1002/path.4024. Epub 2012 May 8.

11.

MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency.

Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, Morgan M, Kemp CJ, Grandori C.

Mol Cancer Res. 2012 Apr;10(4):535-45. doi: 10.1158/1541-7786.MCR-11-0508. Epub 2012 Feb 1.

12.

Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression.

Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ.

Cancer Res. 2011 Aug 1;71(15):5090-100. doi: 10.1158/0008-5472.CAN-11-0568. Epub 2011 Jun 8.

13.

Plasma proteome profiles associated with inflammation, angiogenesis, and cancer.

Kelly-Spratt KS, Pitteri SJ, Gurley KE, Liggitt D, Chin A, Kennedy J, Wong CH, Zhang Q, Buson TB, Wang H, Hanash SM, Kemp CJ.

PLoS One. 2011 May 12;6(5):e19721. doi: 10.1371/journal.pone.0019721.

14.

Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.

Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, Moore RJ, Camp DG 2nd, Chodosh LA, Smith RD, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Proteomics Clin Appl. 2011 Apr;5(3-4):179-88. doi: 10.1002/prca.201000037. Epub 2011 Feb 15.

15.

Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer.

Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ.

Oncogene. 2009 Oct 15;28(41):3652-62. doi: 10.1038/onc.2009.226. Epub 2009 Aug 3.

16.

Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer.

Glover CE, Gurley KE, Kim KH, Storer B, Fero ML, Kemp CJ.

Carcinogenesis. 2009 Jun;30(6):1058-63. doi: 10.1093/carcin/bgp089. Epub 2009 Apr 20.

17.

DNA-PK suppresses a p53-independent apoptotic response to DNA damage.

Gurley KE, Moser R, Gu Y, Hasty P, Kemp CJ.

EMBO Rep. 2009 Jan;10(1):87-93. doi: 10.1038/embor.2008.214. Epub 2008 Dec 5.

18.

Tumor suppression by p53 in the absence of Atm.

Bailey SL, Gurley KE, Hoon-Kim K, Kelly-Spratt KS, Kemp CJ.

Mol Cancer Res. 2008 Jul;6(7):1185-92. doi: 10.1158/1541-7786.MCR-07-2009. Epub 2008 Jun 26.

19.

Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues.

Gurley KE, Kemp CJ.

Mol Cancer Res. 2007 Dec;5(12):1312-8. doi: 10.1158/1541-7786.MCR-07-0223.

20.

p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability.

Payne SR, Zhang S, Tsuchiya K, Moser R, Gurley KE, Longton G, deBoer J, Kemp CJ.

Mol Cell Biol. 2008 Jan;28(1):258-68. Epub 2007 Oct 22.

21.

Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.

Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, Piening BD, Feng LC, Kasarda E, Gurley KE, Eng JK, Chodosh LA, Kemp CJ, McIntosh MW, Paulovich AG.

J Proteome Res. 2007 Oct;6(10):3962-75. Epub 2007 Aug 21.

PMID:
17711321
22.

Deficiency in the gap junction protein connexin32 alters p27Kip1 tumor suppression and MAPK activation in a tissue-specific manner.

King TJ, Gurley KE, Prunty J, Shin JL, Kemp CJ, Lampe PD.

Oncogene. 2005 Mar 3;24(10):1718-26.

PMID:
15608667
23.

p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.

Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ.

PLoS Biol. 2004 Aug;2(8):E242. Epub 2004 Aug 17.

24.

Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.

Philipp-Staheli J, Kim KH, Liggitt D, Gurley KE, Longton G, Kemp CJ.

Oncogene. 2004 Jan 29;23(4):905-13.

PMID:
14647411
25.

Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice.

Philipp-Staheli J, Kim KH, Payne SR, Gurley KE, Liggitt D, Longton G, Kemp CJ.

Cancer Cell. 2002 May;1(4):355-68.

26.
27.
29.

Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis.

Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ.

Oncogene. 1999 Aug 19;18(33):4689-98.

30.

The murine gene p27Kip1 is haplo-insufficient for tumour suppression.

Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ.

Nature. 1998 Nov 12;396(6707):177-80.

31.

DNA double-strand breaks, p53, and apoptosis during lymphomagenesis in scid/scid mice.

Gurley KE, Vo K, Kemp CJ.

Cancer Res. 1998 Jul 15;58(14):3111-5.

32.

p53 induction, cell cycle checkpoints, and apoptosis in DNAPK-deficient scid mice.

Gurley KE, Kemp CJ.

Carcinogenesis. 1996 Dec;17(12):2537-42.

PMID:
9006086
33.

Induction of tolerance to heart allografts in rats using posttransplant total lymphoid irradiation and anti-T cell antibodies.

Woodley SL, Gurley KE, Hoffmann SL, Nicolls MR, Hagberg R, Clayberger C, Holm B, Wang X, Hall BM, Strober S.

Transplantation. 1993 Dec;56(6):1443-7.

PMID:
8279017
34.

Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody.

Nicolls MR, Aversa GG, Pearce NW, Spinelli A, Berger MF, Gurley KE, Hall BM.

Transplantation. 1993 Mar;55(3):459-68.

PMID:
8456460
37.

Induction of unresponsiveness to organ allografts. A comparison of different immunosuppressive protocols in DA and WF strains of rats.

Ilano AL, Spinelli A, Gurley KE, Strober S, Hall BM.

Transplantation. 1991 Apr;51(4):905-9. No abstract available.

PMID:
1901677
40.

Mechanisms maintaining antibody-induced enhancement of allografts. II. Mediation of specific suppression by short lived CD4+ T cells.

Pearce NW, Spinelli A, Gurley KE, Dorsch SE, Hall BM.

J Immunol. 1989 Jul 15;143(2):499-506.

PMID:
2472441
42.

Tempo of induction of W3/25+ suppressor cells in cyclosporine-treated rat cardiac allograft recipients.

Hall BM, Gurley KE, Dorsch SE.

Transplant Proc. 1987 Feb;19(1 Pt 1):504. No abstract available.

PMID:
2978917
43.

"The factor of immunization" in allograft rejection: carried by cytotoxic T cells, not helper-inducer T cells.

Gurley KE, Hall BM, Dorsch SE.

Transplant Proc. 1986 Apr;18(2):307-9. No abstract available.

PMID:
2938319
45.

The possible role of cytotoxic T cells in the mediation of first-set allograft rejection.

Hall BM, Gurley KE, Dorsch SE.

Transplantation. 1985 Sep;40(3):336-9. No abstract available.

PMID:
2930923
46.
48.
49.
50.

Bone marrow transplantation following total lymphoid irradiation. I. Correlation with field size and suppressor cell induction.

Lowry RP, Carpenter CB, Gurley KE, Merrill JP.

Transplantation. 1983 Jul;36(1):16-23.

PMID:
6223420

Supplemental Content

Loading ...
Support Center